ECA

Palatin, AstraZenca collaborate in AZD2820 obesity trial

Tuesday, August 16, 2011 10:09 AM

Palatin Technologies and AstraZeneca have initiated the phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.

More... »

Premier Research Groups names VP of human resources

Monday, August 1, 2011 12:44 PM

Premier Research Group has named Mark P. Sneff vice president, human resources. In this role, Sneff will be responsible for the global human resources function and staff in support of Premier Research’s strategic goals.

More... »

Delta Point names Murphy executive account director

Wednesday, July 13, 2011 10:23 AM

Delta Point has named Matt Murphy executive account director.

More... »

AZ, PTC collaborate in oncology

Thursday, June 30, 2011 09:59 AM

AstraZeneca and PTC Therapeutics are joining forces for cancer cures, using PTC's discovery/development technology platform, reported FierceBiotech.  AZ will front an undisclosed amount of cash to work on the first oncology target.

More... »

AstraZeneca could be eyeing Cubist

Monday, May 23, 2011 02:16 PM

Speculation late last week suggested AstraZeneca could be eyeing an acquisition of Cubist Pharmaceuticals, according to a report in The Telegraph.

More... »

Bayer CEO considers merger only if stars are aligned

Thursday, May 5, 2011 12:40 PM

German-based Bayer is open to a “merger of equals” that would enhance its health-care unit without paying a premium for an acquisition, says Bayer’s chief executive officer Marijn Dekkers, according to a Bloomberg report.

More... »

AstraZeneca will demolish research labs in Delaware

Monday, April 25, 2011 01:30 PM

AstraZeneca will tear down three research laboratory buildings at its headquarters in Fairfax, Delaware, as part of its global restructuring, according to delaware online.

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »

AstraZeneca's vandetanib approved for MTC

Thursday, April 7, 2011 11:35 AM

The FDA has approved AstraZeneca’s vandetanib, which is a kinase inhibitor and has no brand name yet, to treat adult patients with late-stage medullary thyroid cancer (MTC) who are ineligible for surgery and who have disease that is growing or causing symptoms. The once-daily oral treatment is the first agency-approved drug for MTC, which is estimated to represent 3%-5% of all thyroid cancer.

More... »